• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在剥脱性青光眼患者中,每天早晚分别应用贝美前列素和贝美前列素/噻吗洛尔固定联合制剂进行治疗,可以实现 24 小时眼压控制。

Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma.

机构信息

Glaucoma Unit, 1st University Department of Ophthalmology, AHEPA Hospital, 1 Kyriakidi Str, Thessaloniki 546 36, Greece.

出版信息

Br J Ophthalmol. 2010 Feb;94(2):209-13. doi: 10.1136/bjo.2008.155317. Epub 2009 Oct 12.

DOI:10.1136/bjo.2008.155317
PMID:19825835
Abstract

AIM

To compare 24 h intraocular pressure (IOP) control of morning and evening administered bimatoprost/timolol fixed combination (BTFC) and evening administered bimatoprost in exfoliative glaucoma (XFG).

METHODS

One eye of 60 XFG patients was included in this prospective, observer-masked, crossover comparison. Following wash-out, all patients received bimatoprost monotherapy for 6 weeks. They were then randomised to morning, or evening, administered BTFC for 3 months and then switched to the opposite therapy.

RESULTS

At baseline, mean 24 h pressure was 29.0 mm Hg. Bimatoprost reduced the mean IOP by 8.1 mm Hg (27.8%, p<0.001). The evening administration of BTFC reduced 24 h IOP to a statistically lower level than morning administration (10.2 mm Hg (35.3%) vs 9.8 mm Hg (33.8%); p=0.005). Both dosing regimens reduced IOP significantly more than bimatoprost (p < or = 0.006, for all time points). A 24 h IOP reduction > or = 30% was seen in 43 patients (72%) with evening BTFC compared with 39 patients (65%) with morning BTFC (p=0.344) and only 24 patients (40%) with bimatoprost monotherapy (p<0.001 vs both BTFC regimens).

CONCLUSION

Both BTFC dosing regimens significantly reduce 24 h IOP in XFG compared with bimatoprost monotherapy. The evening dosing gives rise to statistically better 24 h IOP control and could be considered in these patients.

摘要

目的

比较晨晚间应用比马前列素/噻吗洛尔固定组合制剂(BTFC)和晚间应用比马前列素治疗剥脱性青光眼(XFG)的 24 小时眼压(IOP)控制情况。

方法

本前瞻性、观察者设盲、交叉比较纳入 60 例 XFG 患者的单眼。洗脱期后,所有患者接受比马前列素单药治疗 6 周。然后将他们随机分为晨服或晚间服 BTFC 组,各治疗 3 个月,然后再换用相反的治疗。

结果

基线时,24 小时平均眼压为 29.0mmHg。比马前列素使平均 IOP 降低 8.1mmHg(27.8%,p<0.001)。晚间 BTFC 给药将 24 小时 IOP 降低到统计学上更低的水平,比晨服 BTFC 给药降低更明显(10.2mmHg(35.3%)vs 9.8mmHg(33.8%);p=0.005)。两种给药方案均比比马前列素更显著地降低 IOP(p<0.006,所有时间点)。43 例(72%)晚间 BTFC 患者的 24 小时 IOP 降低幅度>或=30%,而晨服 BTFC 组为 39 例(65%)(p=0.344),比马前列素单药组仅为 24 例(40%)(p<0.001 比两种 BTFC 方案)。

结论

与比马前列素单药治疗相比,晨晚间 BTFC 给药方案均显著降低 XFG 的 24 小时 IOP。晚间给药可获得统计学上更好的 24 小时 IOP 控制,可考虑用于此类患者。

相似文献

1
Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma.在剥脱性青光眼患者中,每天早晚分别应用贝美前列素和贝美前列素/噻吗洛尔固定联合制剂进行治疗,可以实现 24 小时眼压控制。
Br J Ophthalmol. 2010 Feb;94(2):209-13. doi: 10.1136/bjo.2008.155317. Epub 2009 Oct 12.
2
Intraocular pressure control over 24 hours using travoprost and timolol fixed combination administered in the morning or evening in primary open-angle and exfoliative glaucoma.在原发性开角型青光眼和剥脱性青光眼患者中,使用曲伏前列素和噻吗洛尔固定复方制剂于早晨或晚上给药,对眼压进行24小时控制。
Acta Ophthalmol. 2009 Feb;87(1):71-6. doi: 10.1111/j.1755-3768.2007.01145.x.
3
24-hour efficacy of the bimatoprost-timolol fixed combination versus latanoprost as first choice therapy in subjects with high-pressure exfoliation syndrome and glaucoma.在高眼压剥脱综合征和青光眼患者中,作为首选治疗药物,比马前列素-噻吗洛尔固定组合制剂与拉坦前列素的 24 小时疗效比较。
Br J Ophthalmol. 2013 Jul;97(7):857-61. doi: 10.1136/bjophthalmol-2012-302843. Epub 2013 May 18.
4
Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.评估青光眼药物疗效的24小时眼压研究的荟萃分析。
Ophthalmology. 2008 Jul;115(7):1117-1122.e1. doi: 10.1016/j.ophtha.2007.10.004. Epub 2008 Feb 20.
5
Bimatoprost and bimatoprost/timolol fixed combination in patients with open-angle glaucoma and ocular hypertension.比马前列素和贝美前列素/噻吗洛尔固定组合在开角型青光眼和高眼压症患者中的应用。
J Ocul Pharmacol Ther. 2011 Feb;27(1):67-71. doi: 10.1089/jop.2010.0090. Epub 2011 Jan 7.
6
Comparison of Travoprost and Bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with latanoprost plus timolol fixed combination.比较曲伏前列素和贝美前列素加噻吗洛尔固定组合在以前用拉坦前列素加噻吗洛尔固定组合治疗的开角型青光眼患者中的疗效。
Am J Ophthalmol. 2010 Oct;150(4):575-80. doi: 10.1016/j.ajo.2010.05.003. Epub 2010 Aug 4.
7
Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma.在原发性开角型青光眼患者中,当曲伏前列素/马来酸噻吗洛尔固定复方制剂与曲伏前列素均于晚上给药时,二者对24小时眼压的控制情况比较
Br J Ophthalmol. 2009 Apr;93(4):481-5. doi: 10.1136/bjo.2008.147322. Epub 2008 Nov 19.
8
Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.比马前列素与拉坦前列素和噻吗洛尔固定组合对昼夜眼压影响的比较。
Ophthalmology. 2007 Dec;114(12):2244-51. doi: 10.1016/j.ophtha.2007.01.025. Epub 2007 Apr 25.
9
A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma.比马前列素/噻吗洛尔固定复方制剂与拉坦前列素/噻吗洛尔固定复方制剂治疗开角型青光眼患者的安全性及降眼压效果比较
Curr Med Res Opin. 2007 May;23(5):1025-32. doi: 10.1185/030079907x182149.
10
Diurnal IOP control with bimatoprost versus latanoprost in exfoliative glaucoma: a crossover, observer-masked, three-centre study.比马前列素与拉坦前列素用于剥脱性青光眼的日间眼压控制:一项交叉、观察者盲法的三中心研究。
Br J Ophthalmol. 2007 Jun;91(6):757-60. doi: 10.1136/bjo.2006.106690. Epub 2006 Nov 23.

引用本文的文献

1
From Eye Care to Hair Growth: Bimatoprost.从眼部护理到头发生长:比马前列素。
Pharmaceuticals (Basel). 2024 Apr 27;17(5):561. doi: 10.3390/ph17050561.
2
Pseudoexfoliation Glaucoma: Clinical Presentation and Therapeutic Options.特发性晶状体前囊下皮质混浊(假性剥脱综合征)性青光眼:临床表现和治疗选择。
Turk J Ophthalmol. 2023 Aug 19;53(4):247-256. doi: 10.4274/tjo.galenos.2023.76300.
3
Diurnal and 24-h Intraocular Pressures in Glaucoma: Monitoring Strategies and Impact on Prognosis and Treatment.青光眼的昼夜和 24 小时眼压:监测策略及其对预后和治疗的影响。
Adv Ther. 2018 Nov;35(11):1775-1804. doi: 10.1007/s12325-018-0812-z. Epub 2018 Oct 20.
4
Genetics, Diagnosis, and Monitoring of Pseudoexfoliation Glaucoma.假性剥脱性青光眼的遗传学、诊断与监测
Curr Ophthalmol Rep. 2016 Dec;4(4):206-212. doi: 10.1007/s40135-016-0113-0. Epub 2016 Oct 11.
5
24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy.在使用含防腐剂的拉坦前列素单药治疗控制不佳的开角型青光眼患者中,单独使用无防腐剂的他氟前列素以及联合使用无防腐剂的多佐胺/噻吗洛尔固定复方制剂的24小时疗效和眼表健康情况
Adv Ther. 2017 Jan;34(1):221-235. doi: 10.1007/s12325-016-0448-9. Epub 2016 Dec 2.
6
24-h Efficacy of Glaucoma Treatment Options.青光眼治疗方案的24小时疗效
Adv Ther. 2016 Apr;33(4):481-517. doi: 10.1007/s12325-016-0302-0. Epub 2016 Feb 24.
7
Management of exfoliative glaucoma: challenges and solutions.剥脱性青光眼的管理:挑战与解决方案。
Clin Ophthalmol. 2015 May 22;9:907-19. doi: 10.2147/OPTH.S77570. eCollection 2015.
8
The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies.马来酸噻吗洛尔对固定复方青光眼治疗方案眼部耐受性的影响。
Clin Ophthalmol. 2014 Dec 12;8:2541-9. doi: 10.2147/OPTH.S76053. eCollection 2014.
9
A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components.一项为期6个月的研究,比较0.0015%他氟前列素与0.5%噻吗洛尔的无防腐剂固定复方制剂与其各自无防腐剂单一成分的疗效、安全性和耐受性。
Adv Ther. 2014 Dec;31(12):1228-46. doi: 10.1007/s12325-014-0163-3. Epub 2014 Dec 2.
10
Optimal sampling scheme for estimation of intraocular pressure diurnal curves in glaucoma trials.青光眼试验中眼压昼夜曲线估计的最佳抽样方案
Clin Pharmacokinet. 2015 Jan;54(1):95-105. doi: 10.1007/s40262-014-0183-9.